Important: This article is for informational purposes only and does not constitute medical advice. MadeMed is a telehealth platform — it does not provide medical care directly. Medical services are provided by Xpedicare, LLC and its affiliated licensed providers. All prescribing decisions are made by licensed clinicians; not everyone will qualify. MadeMed's medications are compounded and are not FDA-approved finished products. Always consult a qualified healthcare professional before starting any prescription treatment.
I spent a few months testing the gelatin trick, baking soda versions, seed-based formulas, and thermogenic blends for this site. Some of those worked modestly. None of them came close to what physician-supervised GLP-1 programs are showing in clinical literature. So when I started researching what an actual compounded GLP-1 program looks like — and more specifically, what it costs to access one without insurance — MadeMed kept coming up.
It's not one of the loudest names in the space. MEDVi and Hims dominate the ad spend. But MadeMed's published pricing is at the low end of what I've seen across the compounded GLP-1 telehealth market, and the platform has a few structural details worth understanding before you decide whether it belongs in your shortlist.
This is what I found.
What MadeMed Actually Is
MadeMed is a telehealth platform operated by IDL Health LLC, registered in Houston, Texas. The platform connects patients with licensed providers through a partner medical group — Xpedicare, LLC — which is an independent professional entity responsible for all clinical decisions. MadeMed itself does not provide medical advice or prescriptions directly. This three-entity structure (platform, medical group, pharmacy) is standard in the telehealth industry and matters because it clarifies who is responsible for what when something goes wrong.
The partner pharmacy handling fulfillment is AbsoluteRx, with Red Rock Pharmacy also referenced in company materials. Medications ship directly to patients after a licensed provider approves the prescription.
Two credentialing signals worth noting: MadeMed holds LegitScript certification and Authorize.net Preferred Reseller status. LegitScript is an independent third-party verification that evaluates telehealth companies against compliance and licensing standards — major payment processors require it. These aren't guarantees of clinical quality, but they are verifiable signals that the platform is operating within recognized compliance frameworks.
What Medications MadeMed Offers
MadeMed's weight loss programs center on four GLP-1 formats. For semaglutide, they offer both the standard weekly injection and an oral sublingual tablet taken daily. For tirzepatide — the dual GIP/GLP-1 agonist — they similarly offer both injectable and oral sublingual formats.
The sublingual (under-the-tongue) oral format is worth flagging specifically. Injectable semaglutide and tirzepatide have extensive clinical trial data behind them — the STEP trials for branded semaglutide showed approximately 15 to 17 percent mean body weight loss over 68 weeks in peer-reviewed published research, and SURMOUNT-5, the first head-to-head randomized controlled trial, showed tirzepatide produced 20.2 percent mean weight loss versus 13.7 percent for semaglutide. Those figures are for injectable branded medications studied in formal trials, not for compounded sublingual formulations.
Compounded oral sublingual GLP-1 absorption is an open question in the current literature. Published pharmacokinetic data for sublingual delivery of these compounds is limited, and at least one legal challenge has raised questions about whether compounded oral tirzepatide achieves therapeutic absorption through that delivery pathway. This is something to discuss directly with a prescribing clinician rather than assume either way.
Beyond weight loss, MadeMed also offers tadalafil for sexual health, injectable and oral sermorelin under its peptide therapy category, and NAD+ in both injectable and nasal spray formats.
How the Enrollment Process Works
The enrollment process follows the standard telehealth model. You complete an online health questionnaire covering your medical history, current medications, and weight loss goals. A licensed provider from Xpedicare reviews your submission and determines whether GLP-1 treatment is medically appropriate. If a prescription is approved, it goes to the partner pharmacy for fulfillment and ships directly to you.
MadeMed does not guarantee a prescription will be written — the decision rests entirely with the prescribing clinician. The platform is also explicit that providers do not prescribe DEA-controlled substances.
Services operate on a subscription model with recurring charges every 30 or 90 days, depending on the plan. You can cancel by emailing [email protected] or through the account portal. Cancellations take effect at the end of the current billing period. The Terms of Use state no prorated refunds are offered.
Pricing: What Published Numbers Show
Based on publicly available information verified across multiple sources, MadeMed programs range from approximately $99 to $269 per month depending on medication type, dose level, and membership status. Oral sublingual semaglutide has been cited at approximately $169 per month at starter pricing. The company also offers a MadeMed Club membership that appears to reduce per-month costs — exact membership pricing should be verified directly at mademed.com, as it was not independently confirmed in public sources at the time this was written.
All programs are cash-pay. No insurance billing. This is standard across compounded GLP-1 telehealth platforms. For context on how this pricing sits in the market, I've covered a more detailed side-by-side comparison in MadeMed vs. MEDVi: Which Compounded GLP-1 Telehealth Platform Makes More Sense in 2026.
The Regulatory Context You Need to Understand
This is the section most review sites skip, and it's the one that matters most for making an informed decision in 2026.
The FDA declared the semaglutide drug shortage resolved on February 21, 2025. Tirzepatide's shortage was resolved on December 19, 2024. During shortage periods, compounding pharmacies had broader legal authority to produce these medications under Section 503A of the Federal Food, Drug, and Cosmetic Act. With shortages resolved, that authority has narrowed, and the FDA has taken enforcement action against multiple telehealth platforms for misbranding and marketing violations. More than 30 telehealth companies received warning letters in early 2026.
MadeMed's own Terms of Use acknowledge this directly: “Compounded drugs are not approved by the Food and Drug Administration (FDA) and are not evaluated for safety or efficacy.” That level of transparency in the platform's own legal documentation is worth noting — and worth reading before enrolling.
The regulatory environment for compounded GLP-1s continues to shift. Major platforms have already pivoted: in March 2026, Hims and Hers announced a settlement with Novo Nordisk and exited compounded GLP-1 marketing in favor of branded products. What this means for smaller compounding-focused platforms is not fully resolved. If you're considering a compounded program, verifying the platform's current LegitScript status and reviewing its most recent Terms of Use before enrolling is practical due diligence.
What MadeMed Is Genuinely Good For
If you're an adult who doesn't have insurance coverage for branded GLP-1 medications like Wegovy or Zepbound — and the $1,000+ per month cash-pay price for branded options is genuinely out of reach — compounded GLP-1 programs through platforms like MadeMed represent one of the more accessible entry points currently available. The $99 to $269 range is among the lowest published pricing in the compounded telehealth market.
The platform is also a reasonable fit for people who prefer a needle-free format. The oral sublingual options exist for both semaglutide and tirzepatide, which addresses needle aversion — though again, the absorption data for sublingual delivery differs from the injectable trials that established GLP-1 efficacy.
What it's not: a substitute for ongoing medical oversight. The telehealth model connects you with a provider for the initial evaluation and prescription, but longitudinal management of GLP-1 therapy — dose titration, side effect management, monitoring for contraindications — requires an active relationship with a clinician who knows your full medical history.
My Honest Assessment
MadeMed has the structural elements I look for when assessing a telehealth platform's legitimacy: verified entity registration, named medical group separation, named pharmacy partners, LegitScript certification, and transparent disclosure of compounding status in its own legal documentation. That's a better compliance posture than some platforms I've seen in this space.
The pricing is genuinely competitive. The $99 entry point for certain formats is among the lowest I've found in current published data across compounded semaglutide providers.
The things I'd want answered before enrolling: current state availability for my specific medication, exact MadeMed Club membership terms, and whether the injectable or sublingual format is more appropriate for my clinical situation — a question for the prescribing clinician, not the intake form.
For a detailed breakdown of how MadeMed's pricing and program structure compares to MEDVi — the other platform I've covered in depth — see my comparison piece here. And if you're still in the early research phase on whether GLP-1 therapy makes sense at all versus other approaches, my MadeMed pricing and how-it-works breakdown walks through the enrollment steps and cost math in more detail.
Frequently Asked Questions
Is MadeMed legit?
MadeMed operates as IDL Health LLC, a registered company based in Houston, TX. It holds LegitScript certification and Authorize.net Preferred Reseller status. Medical services are provided by an independent group, Xpedicare, LLC. These are verifiable legitimacy signals. Whether the platform is right for you depends on your individual health situation and a conversation with the prescribing clinician.
What medications does MadeMed offer?
MadeMed offers compounded injectable semaglutide, oral sublingual semaglutide, injectable tirzepatide, and oral sublingual tirzepatide for weight loss. It also offers tadalafil for sexual health, injectable and oral sermorelin for peptide therapy, and NAD+ injectable and nasal spray.
Are MadeMed's medications FDA-approved?
No. MadeMed's medications are compounded by partner pharmacies. Compounded drugs are not FDA-approved finished products and have not been independently evaluated by the FDA for safety or efficacy. This is disclosed in MadeMed's own Terms of Use.
What does MadeMed cost?
Published pricing ranges from approximately $99 to $269 per month depending on medication, dose, and membership status. MadeMed operates on a cash-pay basis with no insurance billing. Pricing should be verified directly at mademed.com before enrolling, as rates can change.
What states is MadeMed available in?
MadeMed is available in approximately 40 states. Availability varies by medication and state law. Verify current state availability on the MadeMed website before starting an enrollment.
Leave a Reply
You must be logged in to post a comment.